Navigation Links
Study opens new prospects for developing new targeted therapies for breast cancer
Date:5/2/2013

Lugano-CH, Brussels-BE, 2 May 2013 -- A study led by prominent breast cancer experts from Europe and the US has revealed a number of potentially important prospects for targeted therapies, and brings opportunities of truly personalised therapy for breast cancer a step closer, researchers said at the 5th IMPAKT Breast Cancer Conference in Brussels, Belgium.

The IMPAKT meeting presents cutting edge, 'translational' breast cancer research that is beginning to have an impact for patients.

This current study was led by Dr Martine Piccart, Director of Medicine at the Jules Bordet Institute in Brussels, and Dr Jose Baselga, Associate Director at Memorial Sloan-Kettering Cancer Center, New York.

The researchers used modern sequencing technology to characterise the genetic aberrations of cancer genes present in tumour samples from a well-defined cohort of advanced postmenopausal patients who were enrolled in the BOLERO-2 clinical trial.

"The results of this study generated hypotheses for developing more rational targeted therapy combinations based on the specific genetic aberrations present in each individual tumour," Dr Piccart said.

"This work, together with previous works published last year, highlights again the genetic heterogeneity of breast cancer. These results show that tumours that may look very similar at the clinical level, can be genetically very different, suggesting that they may require different treatment strategies."

"There is still a long way to go before we will be able to offer truly personalised therapies to cancer patients, and support for research such as this will be critical to accelerate this process," Dr Piccart said.

The study involved postmenopausal women with advanced breast cancer that was hormone receptor positive and HER2 negative taking part in the BOLERO-2 phase III trial. The trial showed that everolimus plus exemestane significantly improved progression-free survival, response rate and clinical benefi
'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. Law that regulates shark fishery is too liberal: UBC study
3. New study will help protect vulnerable birds from impacts of climate change
4. Study jointly led by UCSB researcher supports theory of extraterrestrial impact
5. BYU study: Using a gun in bear encounters doesnt make you safer
6. 15-year study: When it comes to creating wetlands, Mother Nature is in charge
7. Pycnogenol (French maritime pine bark extract) shown to improve menopause symptoms in new study
8. Crystal structure of archael chromatin clarified in new study
9. EU-funded study underlines importance of Congo Basin for global climate and biodiversity
10. University of Houston study shows BP oil spill hurt marshes, but recovery possible
11. Study demonstrates cells can acquire new functions through transcriptional regulatory network
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 5, 2015 In Brazil , ... already using these solutions and 42 percent planning to invest ... approximately 25 percent of the companies will be investing in ... majority of companies in the region are currently opting for ... model will command significant attention in the coming years. This ...
(Date:3/2/2015)... March 2, 2015 Synaptics Inc. (NASDAQ: ... human interface solutions, today announced a new implementation ... to enable rapid and secure transactions and reliable ... gaming is a turnkey solution providing mouse and ... quickly integrate fingerprint ID solutions into their product ...
(Date:2/25/2015)... , Feb. 25, 2015  ABC Financial Services ... in the Health and Fitness Industry, today announced ... to MYiCLUBonline.  The latest upgrade includes advances to ... of cardless check-in via Identity One fingerprint biometrics. ... time through interactive displays at the International Health, ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3ABC Financial Unveils New Software Enhancements 2ABC Financial Unveils New Software Enhancements 3
... 2011 Based on its recent analysis of ... recognizes Cardiocom with the 2011 North American Frost ... integrated clinical telehealth services that offer significant cost ...   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) Cardiocom combines advanced ...
... Inexpensive igloo-shaped, pollution-eating devices nicknamed "Poo-Gloos" can ... treatment facilities for towns outgrowing their waste-treatment lagoons, ... results of this study show that it is ... hundreds of thousands, if not millions of dollars, ...
... rethinking what happens on the surface of things, engineers ... biofilm colonies exhibit an unmatched ability to repel ... across yet only hundreds of microns thick, such slimy ... pipes to teeth and are notoriously resistant to antimicrobial ...
Cached Biology News:Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 2Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 3Frost & Sullivan Recognizes Cardiocom as a Technology Enabler for Superior Cost-Effective Remote Chronic Care Management 4Igloo-shaped 'Poo-Gloos' eat sewage 2Igloo-shaped 'Poo-Gloos' eat sewage 3Igloo-shaped 'Poo-Gloos' eat sewage 4Igloo-shaped 'Poo-Gloos' eat sewage 5A pesky bacterial slime reveals its survival secrets 2A pesky bacterial slime reveals its survival secrets 3
(Date:3/27/2015)... 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: CASI ... and commercialization of innovative therapeutics addressing cancer and other ... commercial focus on China , today ... ended December 31, 2014.  The Company ... per share, for the three months ended December 31, ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 PRC Clinical, ... announced today several management and executive appointments effective immediately. ... Financial Officer (CFO) and member of the Board of ... Business Operations, and Sue Dowden will assume the position ... and current Chief Operations Officer (COO), has been appointed ...
(Date:3/26/2015)...  BioNano Genomics, Inc., the leader in genome mapping, ... chief commercial officer. Salyer has more than 20 years ... life sciences. At BioNano, Salyer will oversee the commercialization ... to assemble a comprehensive view of complex genomes to ... institutions located in the United States ...
(Date:3/26/2015)... March 26, 2015 PAREXEL International ... clinical research organization , announced today ... agreement to acquire all of the business ... leading provider of specialized pharmacovigilance services, based ... collection, detection, assessment, monitoring, and prevention of ...
Breaking Biology Technology:CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 2PRC Clinical Announces Key Management Appointments and Launches East Coast Operations 3BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 2PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 3PAREXEL Announces Execution of Definitive Agreement to Acquire Quantum Solutions India, Strengthening Leadership In Pharmacovigilance Services 4
... Mass., Nov. 9, 2010 Boston Scientific Corporation (NYSE: ... of its Vercise™ Deep Brain Stimulation (DBS) System as ... multi-center, prospective trial designed to examine the improvement of ... the Vercise DBS System for the treatment of Parkinson,s ...
... novel, real-time imaging system, scientists have tracked a group ... lungs, into the body and out again, providing a ... particles which could be used in developing therapeutic agents ... greater understanding of the health effects of air pollution. ...
... (Nasdaq: KNDL ), a leading, global full-service ... the third quarter of 2010 of $131.4 million. Contract ... to $10.4 million or 1.3 percent of the Company,s ... book-to-bill of 1.5. New business authorizations (backlog) at Sept. ...
Cached Biology Technology:Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 2Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 3Boston Scientific Begins Patient Enrollment in Clinical Trial Assessing Deep Brain Stimulation for Parkinson's Disease 4Scientist chronicle nanoparticles' journey from the lungs into the body 2Scientist chronicle nanoparticles' journey from the lungs into the body 3Kendle Announces Third Quarter 2010 Results 2Kendle Announces Third Quarter 2010 Results 3Kendle Announces Third Quarter 2010 Results 4Kendle Announces Third Quarter 2010 Results 5Kendle Announces Third Quarter 2010 Results 6
... cDNA normalization is essential for ... using high-throughput approaches, such as EST ... Most normalization methods are not well ... cDNA. The Evrogen TRIMMER kit, though, ...
... Tecan has 20 years of expertise ... (ELISA), and still offers the most powerful ... manages up to 40 000 in-microplate tests ... The integration of different modules (such as ...
... 6 delivers enhanced statistics and statistical ... quality improvement managers. As an accepted ... 6 simplifies statistics for novice users ... by experts. It offers a powerful ...
Glycerol-based mounting medium for immunofluorescence microscopy. Formulated to retard photobleaching of fluorochromes such as fluorescein and rhodamine. Product can also be used as a diluent for fl...
Biology Products: